Skip to content
Baltimore News Journal – Lifestyle
Author:
BioVie, Inc.
BioVie Updates Parkinson’s Phase 3 Program, FDA Engagement
September 8, 2026
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease
August 6, 2026
Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2
May 27, 2026
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
May 26, 2026
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease
May 18, 2026
←
Previous Page
1
2